How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Haemorrhoidal Energy Therapy (HET) Market
- By Therapy Type: Infrared Coagulation, Rubber Band Ligation, Sclerotherapy, Electrotherapy, Cryotherapy
- By Patient Type: Adult Patients, Geriatric Patients, Pediatric Patients
- By Treatment Setting: Hospital-based Treatment, Clinic-based Treatment, Ambulatory Surgical Centers, Home Care
- By End User: Proctology Clinics, General Hospitals, Specialty Clinics, Outpatient Surgical Centers
- By Technology Type: Non-invasive Devices, Minimally Invasive Devices, Surgical Instruments
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Infrared Coagulation leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 9 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 9 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Haemorrhoidal Energy Therapy (HET) Market report
A complete, evidence-based study - 12 chapters and 116 sections covering market size, segmentation across 5 axes, regional analysis and 9 company profiles, forecast to 2033.
Segmentation covered
Therapy Type 5
Patient Type 3
Treatment Setting 4
End User 4
Technology Type 3
Companies profiled
Medtronic
Johnson & Johnson
Boston Scientific
Micro-Tech Endoscopy
ConMed
Cook Medical
Rocket Medical
THD SpA
Jiangsu Kangjin Medical Instrument
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
9 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Boston Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Micro-Tech Endoscopy
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ConMed
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Cook Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Rocket Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →THD SpA
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.196 →Jiangsu Kangjin Medical Instrument
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,066M by 2033 · 7.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Infrared Coagulation53.4
- Rubber Band Ligation15.5
- Sclerotherapy10.6
- Electrotherapy7.2
- Cryotherapy13.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,712M → $3,272M · 8.4%
Europe$1,193M → $1,864M · 5.7%
Asia Pacific$1,090M → $2,093M · 8.5%
Latin America$674.5M → $1,199M · 7.5%
Middle East and Africa$518.9M → $820.5M · 5.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.182026
7.202027
7.212028
7.222029
7.222030
7.232031
7.252032
7.262033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic12.4
- Johnson & Johnson21.2
- Boston Scientific7.5
- Micro-Tech Endoscopy13.9
- ConMed11.9
- Cook Medical5.2
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapy Type21.3%
Patient Type17.7%
Treatment Setting26.0%
End User22.4%
Technology Type12.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.4
- Europe20.2
- Asia Pacific22.6
- Latin America13.0
- Middle East and Africa8.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic | 74 | 86 | 87 | 98 | 91 | 80 | 86 |
| Johnson & Johnson | 90 | 71 | 88 | 93 | 88 | 76 | 84 |
| Boston Scientific | 70 | 87 | 73 | 72 | 68 | 81 | 75 |
| Micro-Tech Endoscopy | 81 | 61 | 58 | 82 | 66 | 60 | 68 |
| ConMed | 76 | 65 | 70 | 69 | 67 | 56 | 67 |
| Cook Medical | 65 | 50 | 60 | 63 | 53 | 64 | 59 |
| Rocket Medical | 62 | 66 | 63 | 60 | 65 | 54 | 62 |
| THD SpA | 43 | 59 | 42 | 49 | 39 | 52 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic
- Johnson & Johnson
- Boston Scientific
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Johnson & Johnson | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Boston Scientific | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Micro-Tech Endoscopy | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| ConMed | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Cook Medical | ◐ | − | ◐ | ◐ | − | ◐ |
| Rocket Medical | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| THD SpA | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic86
2Johnson & Johnson84
3Boston Scientific75
4Micro-Tech Endoscopy68
5ConMed67
6Rocket Medical62
7Cook Medical59
8THD SpA47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
MedtronicJohnson & Johnson
Challenger3
Strong scale, closing on the leaders.
Boston ScientificMicro-Tech EndoscopyConMed
Contender2
Focused players with pockets of strength.
Cook MedicalRocket Medical
Niche1
Specialists in a single segment or region.
THD SpA
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapy Type in North America, then scale across Haemorrhoidal Energy Therapy (HET) Market — a $479M beachhead inside a $8.77B market.
Beachhead (SOM)$479Mobtainable near-term
Serviceable (SAM)$3.29Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Infrared Coagulation
Best fit — highest urgency & budget in Therapy Type.
Economic buyer78 fit
Rubber Band Ligation
Strong fit — clear ROI and a fast path to value.
End user69 fit
Sclerotherapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Patient Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Treatment Setting
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve18%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Haemorrhoidal Energy Therapy (HET) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified22%
Evaluation15%
Closed-won7%
$12.6KCAC
$44KLTV
3.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Haemorrhoidal Energy Therapy (HET) Market is a resilient opportunity — $5.75B by 2033, compounding at 4.9%.
TAM · 2025$3.91Btoday
TAM · 2033$5.75Bforecast
CAGR4.9%2027–2033
Cumulative$43.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.75BTotal addressable market
SAM$1.96BServiceable available market
SOM$420MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.9% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
9+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.75BLarge & growingTAM by 2033 at 4.9% CAGR
$1.96BServiceable nowreachable with today’s model
$420MBeachhead winobtainable near-term share
9+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.49BBear3.2% CAGR
$5.75BBase4.9% CAGR
$7.37BBull6.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Patient Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Haemorrhoidal Energy Therapy (HET) Market — a $4.76B market by 2033. Plan: grow share from 10.7% to 18.7%.
Market size · 2033$4.76Btotal addressable
Market CAGR11.4%2027–2033
Target share18.7%from 10.7% today
Revenue ambition$890Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.7% | 18.7% | On track |
| Revenue | $521M | $890M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 38.0% | 41.8% | At risk |
| Customer retention | 89.7% | 96.3% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Patient Type capability
A defensible second engine — invest in Patient Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Patient Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $92M capacity & capability investment
- Greenlight bolt-on M&A in Patient Type
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Haemorrhoidal Energy Therapy (HET) Market conversation — a $2.74B market you can size, segment and defend in minutes.
Market size · 2033$2.74Btotal opportunity
Growth4.6%CAGR to 2033
Addressable buyers904+accounts in scope
Typical ROI6.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.9×return on cost, year one
< 3 mopayback period
$80K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
9+players profiled in this market
Coverage includes
MedtronicJohnson & JohnsonBoston ScientificMicro-Tech EndoscopyConMedCook MedicalRocket MedicalTHD SpA+1 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Haemorrhoidal Energy Therapy (HET) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Haemorrhoidal Energy Therapy (HET) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Haemorrhoidal Circular Stapler Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportHaemorrhagic Stroke Treatment Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportHaemophilus Parasuis Bivalent Vaccine Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportHaemophilus Influenzae Type B Injection Vaccine Market
Market size, share, segmentation and regional forecast.
$510M market · 2025 base year
View reportHaemophilus Influenzae Type b Conjugate Vaccine Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportHaemophilus Influenzae Infection Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportHaemophilus b Conjugate Vaccine (Hib) Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportHaemophilia Drug Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportHaemoglobinometers Market
Market size, share, segmentation and regional forecast.
$942M market · 2025 base year
View reportHaemodialysis Machine Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportHaemodialysis Concentrates Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportHaemodiafiltration (HDF) Machine Market
Market size, share, segmentation and regional forecast.
$353M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.